Company / Current Assets
Protalix BioTherapeutics, Inc. Current Assets History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$66.7M
FY2025
5-year range
$44.9M / $69.9M
FY2021-FY2025
Trend
+11.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 10 years, ranging from $32M in FY2019 to $86M in FY2015.
Based on SEC 10-K filings.
$67M in FY2025 with a 10-year CAGR of -2.5%.
Declined from $70M to $67M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +14.1%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -2.5%
Key checks
Key Insights
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, current assets increased 11.0% year-over-year.
- Peak current assets was recorded in FY2015.
- Lowest current assets in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $66.7M | +11.0% |
| FY2024 | $60.1M | -14.1% |
| FY2023 | $69.9M | +55.8% |
| FY2022 | $44.9M | -27.2% |
| FY2021 | $61.7M | +10.7% |
| FY2020 | $55.7M | +71.6% |
| FY2019 | $32.5M | -48.2% |
| FY2017 | $62.7M | -12.8% |
| FY2016 | $71.9M | -16.3% |
| FY2015 | $85.9M | +31.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026